ADAG in “China Becomes Pharma's Global R&D Engine”
Adagene Inc.
Adagene gives public-market exposure to a China-founded antibody-engineering platform pursuing globally partnered and internally developed immuno-oncology programs.
ADAG impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to ADAG’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading ADAG impact map…
Price history, marked with story events
Feb 12, 2024 – Feb 11, 2025 · 251 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Adagene gives public-market exposure to a China-founded antibody-engineering platform pursuing globally partnered and internally developed immuno-oncology programs.
Read the full China Becomes Pharma's Global R&D Engine story